Human EGF Quantikine PharmPak (50 Plates)

• Supplier: R&D Systems
• Catalog: PDEG00
• Category: ELISA Kit
• Assay Type: Solid Phase Sandwich ELISA
• Sample Type: Cell Culture Supernates (200 µL), Serum (10 µL), EDTA Plasma (200 µL), Heparin Plasma (200 µL), Platelet-poor Citrate Plasma (200 µL), Urine (10 µL)
• Sensitivity: 0.7 pg/mL
• Range: 3.9 - 250 pg/mL (Serum, Heparin Plasma, Cell Culture Supernates, EDTA Plasma, Platelet-poor Citrate Plasma, Urine)
• Format: 96-well strip plate
• Description: The Quantikine Human EGF Immunoassay kit is a 3.5 or 4.5 hour solid phase ELISA designed to measure EGF levels in cell culture supernates, serum, plasma, and urine
• Gene: EGF

Product References

Plasma biomarkers as predictors of outcome in patients with advanced - Plasma biomarkers as predictors of outcome in patients with advanced

Llovet JM, Pena CE, Lathia CD, Shan M, Meinhardt G, Bruix J. Clin Cancer Res. 2012 Apr 15;18(8):2290-300.

Decreased plasma cytokines are associated with low platelet counts in aplastic - Decreased plasma cytokines are associated with low platelet counts in aplastic

Feng X, Scheinberg P, Samsel L, Rios O, Chen J, McCoy JP Jr, Ghanima W, Bussel JB, Young NS. J Thromb Haemost. 2012 Aug;10(8):1616-23.

Activation of HER family signaling as a mechanism of acquired resistance to ALK - Activation of HER family signaling as a mechanism of acquired resistance to ALK

Tanizaki J, Okamoto I, Okabe T, Sakai K, Tanaka K, Hayashi H, Kaneda H, Takezawa K, Kuwata K, Yamaguchi H, Hatashita E, Nishio K, Nakagawa K. Clin Cancer Res. 2012 Nov 15;18(22):6219-26.

Expression and prognostic value of circulating angiogenic cytokines in pancreatic - Expression and prognostic value of circulating angiogenic cytokines in pancreatic

Rahbari NN, Schmidt T, Falk CS, Hinz U, Herber M, Bork U, Buchler MW, Weitz J, Koch M. BMC Cancer. 2011 Jul 5;11:286.

Leptin administered in physiological or pharmacological doses does not regulate - Leptin administered in physiological or pharmacological doses does not regulate

Aronis KN, Diakopoulos KN, Fiorenza CG, Chamberland JP, Mantzoros CS. Diabetologia. 2011 Sep;54(9):2358-67.

Alternatives to the use of fetal bovine serum: human platelet lysates as a serum - Alternatives to the use of fetal bovine serum: human platelet lysates as a serum

Rauch C, Feifel E, Amann EM, Spotl HP, Schennach H, Pfaller W, Gstraunthaler G. ALTEX. 2011;28(4):305-16.

Effect of protein kinase Cbeta inhibition on renal hemodynamic function and - Effect of protein kinase Cbeta inhibition on renal hemodynamic function and

Cherney DZ, Konvalinka A, Zinman B, Diamandis EP, Soosaipillai A, Reich H, Lorraine J, Lai V, Scholey JW, Miller JA. Diabetes Care. 2009 Jan;32(1):91-3.

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 - Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6

Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY. Br J Cancer. 2009 Jan 27;100(2):298-304.

A urinary biomarker profile for children with HIV-associated renal diseases. - A urinary biomarker profile for children with HIV-associated renal diseases.

Soler-Garcia AA, Rakhmanina NY, Mattison PC, Ray PE. Kidney Int. 2009 Jul;76(2):207-14.

Molecular response to cetuximab and efficacy of preoperative cetuximab-based - Molecular response to cetuximab and efficacy of preoperative cetuximab-based

Debucquoy A, Haustermans K, Daemen A, Aydin S, Libbrecht L, Gevaert O, De Moor B, Tejpar S, McBride WH, Penninckx F, Scalliet P, Stroh C, Vlassak S, Sempoux C, Machiels JP. J Clin Oncol. 2009 Jun 10;27(17):2751-7.